PharmAthene snares two vaccines in buyout

Annapolis, MD-based PharmAthene has agreed to fork over up to $40 million to acquire the vaccines unit of the UK's Avecia Biologics. The acquisition--which is being paid for with a mix of cash and milestone paydays--gives PharmAthene two mid-stage vaccines: an anthrax vaccine that has been tested in two Phase II trials and a plague vaccine that is scheduled to enter Phase II. Avecia gets $10 million up front, $10 million more in a year and $20 million in contract milestones.

''There is a tremendous unmet need for a second-generation anthrax vaccine,'' said PharmAthene CEO David Wright. We believe that Avecia's vaccine is uniquely position to meet the current government requirements."

- here's the release
- read the report from the Gazette

Related Articles:
PharmAthene to go public through merger. Report
Siga Technologies, PharmAthene to merge. Report
EMEA panel recommends goat-milk therapy. Report
PharmAthene finds backers for research pact. Report

Suggested Articles

Two weeks after receiving a second dose of Moderna's COVID-19 jab, patients had "robust" levels of neutralizing antibodies against the…

Despite questions about eye-related side effects, GlaxoSmithKline's anti-BCMA treatment emerged from an advisory committee meeting with a 12-0 vote.

After Mallinckrodt's terlipressin beat placebo at reversing kidney failure, an FDA panel will discuss the phase 3 trial's surrogate endpoint.